 |
|
|
| |
Bulevirtide Monotherapy at Low and High Doses in
Patients With Chronic Hepatitis Delta:
24-Week Interim Data of the Phase 3 MYR301 Study
|
| |
| |
EASL International Liver Congress, June 23-26, 2021
Heiner Wedemeyer,1 Soo Aleman,2 Pietro Andreone,3 Antje Blank,4 Maurizia Brunetto,5 Pavel Bogomolov,6 Vladimir Chulanov,7 Natalia Geyvandova,8 Gudrun Hilgard,9
Nina Mamonova,10 Uta Merle,4 Morozov Viacheslav,11 Olga Sagalova,12 Tatyana Stepanova,13 Julian Schulze zur Wiesch,14 Sergey Zotov,15 Stefan Zeuzem,16 Pietro Lampertico17
1Medizinische Hochschule Hannover, Germany; 2 Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden; 3Universitā degli studi di Modena e Reggio Emilia, Italy; 4Universitätsklinikum Heidelberg, Germany; 5UO Epatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; 6M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; 7Central Research Institute of Epidemiology, Moscow; 8Stavropol Regional Clinical Hospital, Stavropol, Russian Federation; 9Universitätsklinikum Essen, Germany; 10National Research Medical Center for Phthisiopulmonology and Infectious Diseases, Moscow; 11Hepatolog, LLC, Samara, Russian Federation; 12Southern Ural State Medical University, Chelyabinsk, Russian Federation; 13Clinic of Modern Medicine, Moscow;
14Universitätsklinikum Hamburg-Eppendorf, Medizinische Klinik Studienambulanz Hepatologie, Hamburg, Germany; 15Specialized Clinical Infectious Diseases Hospital, Krasnodar, Russian Federation; 16Universitätsklinikum Frankfurt, Germany; 17Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, CRC "A.M. and A. Migliavacca" Center for Liver Disease, Universitā degli Studi di Milano, Italy
|
| |
|
|
|
|
|
